Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size By Type (Riluzole, Edaravone (Radicava)), By Application (Hospital, Drugs Store), By Region, And Segment Forecasts, 2023 to 2032

The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market was valued at USD 678.2 million in 2023 and is projected to reach USD 1.29 billion by 2031, growing at a CAGR of 8.6% during the forecast period from 2023 to 2031. The market is primarily driven by the increasing prevalence of ALS, growing awareness initiatives, and rising investment in neurodegenerative disease research. ALS, a progressive neurodegenerative disorder affecting nerve cells in the brain and spinal cord, has no definitive cure, which has propelled demand for disease-modifying therapies, symptomatic treatments, and advanced diagnostics.

Drivers:

1. Rising Incidence of ALS:

Globally, the incidence of ALS is increasing, particularly among the aging population. The expanding patient base is fueling the demand for advanced therapeutic interventions and accelerating market growth.

2. Advances in Neurodegenerative Research:

Innovations in gene therapy, RNA-based treatments, and targeted biologics are opening new avenues in ALS treatment. Ongoing clinical trials and FDA fast-track designations for investigational drugs are also propelling market expansion.

3. Government and Nonprofit Support:

Multiple health organizations and ALS associations are investing in awareness, research funding, and improved healthcare infrastructure, facilitating better access to care and treatment.

Restraints:

1. High Cost of Treatment:

The economic burden of ALS treatment—including drug therapies, physical therapy, and long-term care—is significant. The cost factor can limit patient access, particularly in low- and middle-income countries.

2. Limited Efficacy of Existing Therapies:

Current treatment options primarily manage symptoms rather than halt disease progression. This limitation continues to challenge the effectiveness and uptake of available drugs.

Opportunity:

1. Emerging Gene and RNA Therapies:

The evolution of precision medicine, particularly in gene-editing technologies like CRISPR and antisense oligonucleotides (ASOs), presents promising opportunities for disease-modifying treatments in ALS.

2. Expansion into Emerging Markets:

Developing economies are witnessing increasing healthcare investments and improved diagnostic capabilities, creating substantial opportunities for market expansion.

Market by System Type Insights:

By treatment type, the drug therapy segment held the largest market share in 2023. This includes riluzole, edaravone, and recently approved therapies like AMX0035. These treatments aim to slow disease progression and improve patient quality of life. The gene therapy segment is expected to grow at the fastest rate through 2031, driven by ongoing clinical advancements and investor interest.

Market by End-use Insights:

The hospital segment dominated the market in 2023, owing to the availability of specialized neurological care units and multidisciplinary teams. However, the homecare segment is gaining traction, especially for late-stage ALS patients, due to growing demand for palliative and long-term care in familiar environments.

Market by Regional Insights:

North America accounted for the largest revenue share in 2023, driven by robust healthcare infrastructure, high disease awareness, and strong presence of pharmaceutical players. Europe followed closely, benefiting from public funding and regulatory support. The Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare accessibility, particularly in countries like China, Japan, and India.

Competitive Scenario:

Leading players in the global ALS treatment market include Mitsubishi Tanabe Pharma, Amylyx Pharmaceuticals, Ionis Pharmaceuticals, Biogen Inc., BrainStorm Cell Therapeutics, Cytokinetics, and AB Science. Companies are focusing on drug innovation, regulatory approvals, and strategic collaborations to strengthen their positions.

In 2023, Amylyx’s AMX0035 received expanded approval across additional regions following favorable clinical data.

In 2024, Biogen initiated a Phase 3 trial of Tofersen for patients with SOD1-ALS.

In 2025, Cytokinetics announced promising Phase 2 results for its fast skeletal muscle troponin activator in ALS patients.

Scope of Work – Global ALS Treatment Market

Key Market Developments:

October 2023: Mitsubishi Tanabe launched a subcutaneous formulation of edaravone to improve patient compliance.

January 2024: Ionis Pharmaceuticals began clinical evaluation of a novel ASO targeting genetic mutations associated with ALS.

May 2025: Amylyx Pharmaceuticals partnered with a global biotech firm to co-develop next-generation neuroprotective therapies for ALS.

FAQs:

1) What is the current market size of the Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

The market was valued at USD 678.2 million in 2023.

2) What is the major growth driver of the Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

Key growth drivers include the rising prevalence of ALS and advancements in neurodegenerative disease research.

3) Which is the largest region during the forecast period in the Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

North America is the largest region due to advanced healthcare infrastructure and strong R&D support.

4) Which segment accounted for the largest market share in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

The drug therapy segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

Major players include Mitsubishi Tanabe Pharma, Amylyx Pharmaceuticals, Ionis Pharmaceuticals, Biogen Inc., and Cytokinetics.